Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at N...(Month continuous abstinence: NicVAX 200 ...),Health

p=0.027), Placebo=4% (4/100)

-- Most effective schedule selected: Schedule 2 (five injections over six

months)

-- Most effective dose selected: 400 micrograms

-- Threshold antibody level identified and probability of abstinence vs.

antibody levels calculated:

-- Attainment of the antibody threshold at Target Quit Date determines

chronic abstinence

-- Subjects in the therapeutic effect window have a >50% likelihood of

quitting

-- No compensatory smoking or increase in withdrawal symptoms

-- Through the nine months of the Phase 2b trial, NicVAX continues its

attractive safety trends with a favorable adverse events profile and no

difference between placebo and each dose group.

"We are extremely pleased with the NicVAX data and the continued smoking cessation trends we've observed through nine months of this clinical trial," said Dr. Leslie Hudson, Interim President and Chief Executive Officer of Nabi. "Our latest analyses have helped us identify a NicVAX dose that achieves the high antibody levels associated with helping smokers successfully quit smoking and remain abstinent over long periods of time. These analyses have also provided us with data that are extremely important for our ongoing partnering efforts. We believe the full 12-month data will be invaluable as we determine next steps for our clinical development program."

To gain greater perspective on these data, Nabi discussed its nine-month findings with nationally recognized smoking cessation researchers and the National Institute on Drug Abuse (NIDA). Nabi will use these validated and promising nine-month data to advance its partnership discussions surrounding NicVAX.

"The data seen to-date for NicVAX have been extremely encouraging," said Dr. Dorothy Hatsukami, Forster Family Professor in Cancer Prevention and
'/>"/>